Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro

Food and Chemical Toxicology

Volumn 60, Issue , 2013, Pages 83-91

  Johnson, Jodee L ^a   Gonzalez de Mejia, Elvira ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Apigenin; Chemotherapeutic drugs; GSK 3 ; Luteolin; NF B; Pancreatic cancer cells

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; APIGENIN; CISPLATIN; CYTOCHROME C; FLUOROURACIL; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; LUTEOLIN; OXALIPLATIN; TRANSCRIPTION FACTOR RELA;

ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FOOD DRUG INTERACTION; HUMAN; HUMAN CELL; IC 20; IC 50; IN VITRO STUDY; MONOTHERAPY; OUTCOME ASSESSMENT; PANCREAS CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-5-(3-CARBOXYMETHOXYPHENYL)-2-(4-SULFOPHENYL)-2H-TETRAZOLIUM; -APIGENIN; -NUCLEAR FACTOR KAPPA B; -OXALIPLATIN; -ROSWELL PARK MEMORIAL INSTITUTE; 5-FLUOROURACIL; 5-FU; API; APIGENIN; CHEMOTHERAPEUTIC DRUGS; CIS-; CISPLATIN; GEM-; GEMCITABINE; GLYCOGEN SYNTHASE KINASE-3Β; GSK-3Β; GSK-3Β-; LUT-; LUTEOLIN; MTS; NF-ΚB; OXA; PANCREATIC CANCER CELLS; PES-; PHENAZINE ETHOSULFATE; RPMI;

ANTINEOPLASTIC AGENTS; APIGENIN; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DRUG SYNERGISM; FLUOROURACIL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LUTEOLIN; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84881525360     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.07.036     Document Type: Article

References (32)

1. Andersen M.R., Sweet E., Lowe K.A., Standish L.J., Drescher C.W., Goff B.A. Dangerous combinations: ingestible CAM supplement use during chemotherapy in patients with ovarian cancer. J. Altern. Complement. Med. 2013, 18:1-7.
2. Arlt A., Müerköster, Schäfer H. Targeting apoptosis pathways in pancreatic cancer. Cancer Lett. 2010, 332:346-358.
3. Cai X., Lu W., Ye T., Lu M., Wang J., Huo J., Qian S., Wang X., Cao P. The molecular mechanism of luteolin-induced apoptosis is potentially related to inhibition of angiogenesis in human pancreatic carcinoma cells. Oncol. Rep. 2012, 28:1353-1361.
4. ČipáK L., Novotny L., Čipáková I., Rauko P. Differential modulation of cisplatin and doxorubicin efficacies in leukemia cells by flavonoids. Nutr. Res. 2003, 23:1045-1057.
5. Conroy T., Desseigne M., Ychou M., Bouchè O., Guimbaud R., Bècouarn Y., Adenis A., Raoul J., Gourgou-Bourgade S., de la Fouchardière C., Bennouna J., Bachet J., Khemissa-Akouz F., Pèrè-Vergè D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 2011, 364:1817-1825.
6. Deming D., Geiger, Chen H., Kunnimalaiyaan M., Holen K. ZM336372 induces apoptosis associated with phosphorylation of GSK-3β in pancreatic adenocarcinoma cell lines. J. Surg. Res. 2010, 161:28-32.
7. Furukawa T., Duguid W.P., Rosenberg L., Viallet J., Galloway D.A., Tsao M.-S. Long term culture and immortalization of epithelial cells from normal adult human pancreatic ducts by transfection with the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 1996, 148:1763-1770.
8. Gessner P. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995, 105:161-179.
9. Gupta S.C., Hevia D., Patchva S., Park B., Koh W., Aggarwal B.B. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid. Redox Signal. 2012, 16:1295-1322.
10. Hamacher R., Schmid R.M., Saur D., Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer 2008, 7. 10.1186/1476-4598-7-64.
11. Holcomb B., Yip-Schneider M., Schmidt C.M. The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008, 36:225-235.
12. Johnson J., Gonzalez de Mejia E. Dietary factors and pancreatic cancer: the role of food bioactive compounds. Mol. Nutr. Food Res. 2011, 55:58-73.
13. Johnson J., Gonzalez de Mejia E. Flavonoid apigenin modified gene expression associated with inflammation and cancer and induced apoptosis in BxPC-3 human pancreatic cancer cells through inhibition of GSK-3β/NF-κB signaling cascade. Mol. Nutr. Food Res 2013, 10.1002/mnfr.201300307.
14. Johnson J.L., Rupasinghe S.G., Stefani F., Shuler M.A., Gonzalez de Mejia E. Citrus flavonoids luteolin, apigenin, and quercetin inhibit glycogen synthase kinase-3β enzymatic activity by lowering the interaction energy within the binding cavity. J. Med. Food 2011, 14:325-333.
15. Khlebnikov A.I., Schepetkin I.A., Domina N.G., Kirpotina L.N., Quinn M.T. Improved quantitative structure-activity relationship models to predict antioxidant activity of flavonoids in chemical, enzymatic, and cellular systems. Bioorg. Med. Chem. 2007, 15:1749-1770.
16. Kitano A., Shimasaki T., Chikano Y., Nakada M., Hirose M., Higashi T., Ishigaki Y., Endo Y., Takino T., Sato H., Sai Y., Miyamoto K., Motoo Y., Kawakami K., Minamoto T. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS ONE 2013, 8. 10.1371/journal.pone.0055289.
17. Kurata N., Fujita H., Ohuchida K., Mizumoto K., Mahawithitwong P., Sakai H., Onimaru M., Manabe T., Ohtsuka T., Tanaka M. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int. J. Oncol. 2011, 39:473-482.
18. Lee S.H., Ryu J.K., Lee K., Woo S.M., Park J.K., Yoo J.W., Kim Y., Yoon Y.B. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008, 259:39-49.
19. Lin Y., Shi R., Wang X., Shen H. Luteolin, a flavonoid with potentials for cancer prevention and therapy. Curr. Cancer Drug Targets 2008, 8:634-646.
20. Long J., Zhang Y., Yu X., Yang J., LeBrun D.G., Chen C., Yao Q., Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin. Ther. Targets 2011, 15:817-828.
21. Ougolkov A.V., Fernandez-Zapico M.E., Bilim V.N., Smyrk T.C., Chari S.T., Billadeau D.D. Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin. Cancer Res. 2006, 12:5074-5081.
22. Ougolkov A.V., Fernandez-Zapico M.E., Savoy D.N., Urritia R.A., Billadeau D.D. Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res. 2005, 65:2076-2081.
23. Ouyang H., Mou L.-J., Luk C., Liu N., Squire J., Tsao M.-S. Paradiploid human pancreatic duct epithelial cell lines with near normal phenotype. Am. J. Pathol. 2000, 157:1623-1631.
24. Phukan S., Babu V.S., Kannoji A., Hariharan R., Balaji V.N. GSK3β: role in therapeutic landscape and development of modulators. Brit. J. Pharmacol. 2010, 160:1-19.
25. Sak K. Chemotherapy and dietary phytochemical agents. Chemother. Res. Pract. 2012, 2012. 10.1155/2012/282570.
26. Shi X., Liu S., Kleeff J., Friess H., Büchler M. Acquired resistance of pancreatic cancer cells towards 5-fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62:354-362.
27. Shimasaki T., Ishigaki Y., Nakamura Y., Takata T., Nakaya N., Nakajima H., Sato I., Zhao X., Kitano A., Kawakami K., Tanaka T., Takegami T., Tomosugi N., Minamoto T., Motoo Y. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. J.Gastroenterol. 2012, 47:321-333.
28. Shukla S., Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm. Res. 2010, 27:962-978.
29. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63:11-30.
30. Strouch M.J., Milam B.M., Melstrom L.G., McGill J.J., Salabat M.R., Ujiki M.B., Ding X., Bentrem D.J. The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells. Pancreas 2009, 38:409-415.
31. Tempero M.A., Arnoletti J.P., Behrman S.W., Ben-Josef E., Benson A.B., Casper E.S., Cohen S.J., Czito B., Ellenhorn J.D.I., Hawkins W.G., Herman J., Hoffman J.P., Ko A., Komanduri S., Koong A., Ma W.W., Malafa M.P., Merchant N.B., Mulvihill S.J., Muscarella P., Thayer S.P., Whiting S., Wolff R.A., Wolpin B.M., Freedman-Cass D.A., Shead D.A. Pancreatic adenocarcinoma, version 2.2012: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 2012, 10:703-713.
32. Ulbricht C.E., Chao W. Phytochemicals in the oncology setting. Curr. Treat. Options. Oncol. 2010, 11:95-106.